Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial

NEXT STORY
Tetra Bio-Pharma to File PPP001 With the European Medicines Agency
PREV STORY
Genmab Announces European Regulatory Submission for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

American Health Council Names Dr. William Federspiel, PhD, to Education Board

NEW YORK, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Dr. William Federspiel, William Kepler Whiteford ...

author_avatar
NASDAQ Market News

With One of the Fastest-Growing Research Programs in the United States, UVA Engineering Addresses Grand Societal Challenges

New, Strategic Approach Sparks Double-Digit Increases in Sponsored Research FundingCharlottesville, Va., Sept. 07, 2018 ...

author_avatar
NASDAQ Market News

Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting

author_avatar
NASDAQ Market News